Cartography Biosciences launches to accelerate precision immunotherapy

20 July 2022
cartography_big

California, USA-based precision medicine company Cartography Biosciences launched on Tuesday with $57 million in initial funding.

8VC led the company’s Series A financing with strong participation from existing investors Andreessen Horowitz (a16z), which led Cartography’s seed financing, and Wing VC, which was also a seed investor. The Series A financing was joined by new investors Catalio Capital Management, ARTIS Ventures, Alexandria Venture Investments, AME Cloud Ventures, the Cancer Research Institute, and Gaingels.

The company plans to use the proceeds to advance a pipeline of therapeutics designed to broaden the reach of next-generation cancer therapies, as well as conduct a breadth of discovery programs designed to identify novel, best-in-class target antigens across a range of cancer indications.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology